Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Emergent to resume J&J COVID-19 vaccine production at Baltimore plant

07/29/2021 | 06:30pm EDT

July 29 (Reuters) - Emergent BioSolutions said it will resume production of Johnson & Johnson's COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated.

The development was announced late on Wednesday. Last week, J&J slashed 2021 production target of its single-dose vaccine to between 500 million and 600 million doses from its original goal to produce a billion shots.

The resumption follows additional reviews and collaboration with the FDA and manufacturing partners, Emergent Chief Executive Officer Robert Kramer said.

The FDA has so far approved five batches from the Emergent facility since production there was paused, and J&J is working to clear additional doses for use, the drugmaker said last week.

Emergent expects the FDA to approve additional batches of J&J shots, Kramer said during Emergent's Thursday investor call.

U.S. health regulators in April halted operations at the Baltimore plant following a discovery that ingredients from AstraZeneca's COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J's vaccines.

That month, the U.S. government asked Emergent to stop making AstraZeneca shots after it discovered the cross contamination.

"We continue to work collaboratively with AstraZeneca to complete all documents related to their drug substance so they and the U.S. government can make decisions regarding the disposition of this material," Kramer said during the call.

An FDA inspection also turned up a long list of sanitary problems and bad manufacturing practices.

J&J's vaccine, considered more convenient for use, storing and shipping to remote areas, has seen a relatively slow uptake in Europe and the United States due to safety concerns and the production issues.

"We will continue to work toward securing Emergency Use Authorization in the United States for drug substance manufactured at Emergent Bayview as quickly as possible," J&J said in an email.

The FDA did not immediately respond to a Reuters request for comment.

The Wall Street Journal, which first reported the news, cited a letter from the FDA saying the agency had no objections with the plant resuming manufacturing. (https://on.wsj.com/3iXSAfg)

The facility could make as many as 120 million doses a month at full capacity, but the finished doses might not be available until this fall, the Journal reported.

Emergent expects to launch in the near future a late stage study for a COVID-19 therapeutic it is developing in partnership with the U.S. government, executives said on the investor call. (Reporting by Aishwarya Nair, Maria Ponnezhath and Manojna Maddipatla in Bengaluru; Editing by Subhranshu Sahu, Ramakrishnan M. and Shounak Dasgupta)

© Reuters 2021
All news about ASTRAZENECA PLC
12:12pASTRAZENECA : Enhertu demonstrated clinically meaningful and durable response in..
12:06pASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically..
10:50aAstraZeneca Sees Positive Results for Enhertu Trial
10:09aLATEST : FDA panel to offer recommendations on booster shots
09:18aASTRAZENECA : EMA Fails To Find Link Between Blood Clots, AstraZeneca's Vaccine
08:23aASTRAZENECA : Says Imfinzi-Oleclumab Combination Improved Clinical Outcomes for ..
08:06aJOHNSON & JOHNSON : GSA Director Lauded for Luring More People to Get Covid-19 V..
07:31aASTRAZENECA : EU unsure if women face higher risk of clots from AstraZeneca shot
07:31aASTRAZENECA : IMFINZI Combined With Novel Immunotherapies Improved Clinical Outc..
07:11aASTRAZENECA : Buy rating from Morgan Stanley
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 214 M - -
Net income 2021 4 990 M - -
Net Debt 2021 24 654 M - -
P/E ratio 2021 31,5x
Yield 2021 2,51%
Capitalization 174 B 173 B -
EV / Sales 2021 5,64x
EV / Sales 2022 4,56x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 112,31 $
Average target price 136,08 $
Spread / Average Target 21,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC11.16%173 735
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887